医药导报2011，Vol.30Issue(1)：46-49,4.DOI:10.3870/yydb.2011.01.016
莫西沙星对早发无多重耐药危险因素医院获得性肺炎的临床疗效
Clinical Effect of Moxifloxacin in the Treatment of Early and No Risk Factory for MDR Hospital-acquired Pneumonia
摘要
Abstract
Objective To study the clinical effect and prognosis of moxifloxacin in the treatment of early and no risk factory for MDR hospital-acquired pneumonia. Methods 60 cases of early and no risk factory for MDR hospital-acquired pneumonia were randomly divided into moxifloxacin (0.4 g ivgtt qd for 7 d) treatment group(30 cases)and ceftriaxone(2.0 g ivgtt qd for 7 d) treatment group(30 cases). The clinical indicators(CPIS,CRP) .clinical results,clearance of pathogens,prognosis and security were observed. Results After treatment,the efficacy of the treatment group was 83.3％ ,the control was 66.7％. CPIS in the treatment group droped from(6.9±1.1)down to(3. 0±1. 9) ,CRP from(43. 0±5. 1)down to(17. 6±3.9) mg · L-1; while CPIS in the control group declined from(7. 1±1. 4) to(4. 6±1. 7) ,CRP from(41. 5±6. 3) down to(30. 8±4. 4) mg · L-1. The pathogens clearance in the treatment and control groups was 81.0％ and 63. 2％ , respectively. The incidence of later HAP and mortality in the treatment group was 6. 7％ and 3. 3％ , respectively; those in the control group was 16. 7％ and 10. 0％ , respectively. Conclusion Moxifloxacin can improve the clinical symptoms, shorten the course of treatment and improve prognosis for the early and no risk factory for MDR hospital-acquired pneumonia, which is efficient and security.关键词
莫西沙星/肺炎,医院获得性/早发/耐药,多重分类
医药卫生引用本文复制引用
吴春玲,何建新,楼翰健,贾维,陈国钟,滕一鸣,周旭玲,宋秋香,朱捍君,吴亦..莫西沙星对早发无多重耐药危险因素医院获得性肺炎的临床疗效[J].医药导报,2011,30(1):46-49,4.基金项目
浙江省医学会临床科研基金资助项目(基金编号:2008-12) （基金编号:2008-12）
